Inovio's covid-19 vaccine candidate, ino-4800, provides broad cross-reactive immune responses in humans against variants of concern

Plymouth meeting, pa., april 15, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on rapidly bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, and cancer, today announced the results of a study focusing on the human immune responses induced by inovio's dna vaccine candidate for covid-19, ino-4800, against variants of concern.
INO Ratings Summary
INO Quant Ranking